Cromwell Holdings LLC Increases Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Cromwell Holdings LLC increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 94.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 227 shares of the biotechnology company’s stock after acquiring an additional 110 shares during the quarter. Cromwell Holdings LLC’s holdings in Axon Enterprise were worth $91,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AXON. Motley Fool Asset Management LLC grew its position in shares of Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after purchasing an additional 346,838 shares during the period. 1832 Asset Management L.P. purchased a new stake in Axon Enterprise in the 1st quarter valued at about $81,630,000. International Assets Investment Management LLC purchased a new stake in Axon Enterprise in the 3rd quarter valued at about $871,860,000. Vanguard Group Inc. increased its stake in shares of Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after acquiring an additional 212,401 shares during the last quarter. Finally, Swedbank AB purchased a new position in shares of Axon Enterprise during the 1st quarter worth about $39,923,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

Shares of AXON stock opened at $444.52 on Friday. The firm has a fifty day moving average of $396.09 and a two-hundred day moving average of $336.34. The firm has a market cap of $33.55 billion, a P/E ratio of 129.98, a P/E/G ratio of 12.05 and a beta of 0.94. Axon Enterprise, Inc. has a 1-year low of $199.29 and a 1-year high of $455.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s revenue for the quarter was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.80 earnings per share. As a group, research analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Activity

In related news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares in the company, valued at approximately $82,103,253.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Jeri Williams sold 110 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $400.00, for a total value of $44,000.00. Following the completion of the transaction, the director now owns 1,934 shares in the company, valued at approximately $773,600. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 25,811 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the transaction, the president now directly owns 228,166 shares of the company’s stock, valued at approximately $82,103,253.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 371,172 shares of company stock worth $137,000,162. Corporate insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Bank of America initiated coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target for the company. JMP Securities raised their price objective on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Barclays lifted their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $382.85.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.